Pfizer Oncology strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. Our core areas of interest include: Tumor Cell Biology; Bioconjugates Discovery and Development; Precision Medicine; Integrative Biology and Biochemistry; and Immuno- Oncology. In Tumor Cell Biology we are focused on oncogenic drivers, tumor metabolism, and epigenetics. Our Bioconjugates group efforts emphasize our expertise in antibody-drug conjugates (ADCs). Precision Medicine represents an integrated cluster of technology platforms and translational science configured to enable patient-tailored, hypothesis-driven experimental medicine approaches. Our Integrative Biology and Biochemistry team supports novel target identification and validation through functional genomics, proteomics, and other “omic” approaches.

We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

  • Lung, colorectal, breast, ovarian, renal, and hematologic cancers
  • Cancers prevalent in Asia (e.g., gastric cancer, hepatocellular carcinoma)

Specific areas of interest include:

  • Targets and technologies that enable antibody and ADC approaches
  • Oncogenic signaling mechanisms
  • Tumor metabolism
  • Epigenetics
  • Small molecule immuno modulators
  • Directed tumor cell killing via immune-based mechanisms
  • Precision medicine
  • Functional genomics
  • Liquid biopsy technologies
  • Technologies that deliver drugs asymmetrically to specific tissues
  • Targeted nanoparticle technologies and assets


The recent clinical successes reported with cancer immunotherapy are reshaping the field of oncology. Pfizer plans to significantly advance its leadership in this area by partnering to develop cutting edge science beyond the current mainstream immune checkpoints, e.g., CAR-T, vaccinia, and small molecules. The IO programs at Pfizer uniquely leverage a combination of our scientific and clinical strength in immuno-biology alongside our historical expertise in developing first-in-class cancer and vaccine therapies.

Pfizer’s efforts in IO include external collaborative alliances with leading academic medical centers (e.g., MD Anderson) and visionary biotech firms (e.g., Cellectis). Our IO efforts are driven primarily within our Rinat laboratory site in South San Francisco, CA. Leveraging its strength in biotherapeutics alongside core expertise in immuno-biology, Rinat has a strong record of converting validated targets into novel protein-based therapeutics, and advancing molecular and cell-based IO treatments. We would like to partner in the IO space on pre-clinical and clinical stage antibody and small molecule-based immunomodulatory opportunities, with an emphasis on those agents that directly engage or impact T-cell and other tumor infiltrating lymphocyte cell populations.

We are interested in establishing alliances to develop and access:

  • Novel Targets for Overcoming Tumor-induced Immune Resistance

    • Targets that promote immune response whether alone or in combination with checkpoint inhibitors
    • Targets that provide Innate immune support/ activation
    • Targets that reduce immune suppressionCell-based Therapies
  • CAR-T, TCR, and other hybrid targeting modalities with a focus on allogeneic approaches
  • Platform Technologies

    • Mechanisms, biomarkers, and screening approaches to identify and accelerate the most promising combination therapies
    • New modalities to induce immune responses: Bi-specific mAbs, nanoparticles, oncolytic viruses, tumor vaccines, chimeric antigen receptors (CARs), or novel T cell receptors (TCRs)
    • Identification of new immune modulating targets
    • Monitoring of immune-supporting and immune-suppressing biomarkers within the tumor as well as of the anti-tumor immune responses
    • Novel animal models that accurately recapitulate human tumor-immune system interactions

Not actively seeking partnering opportunities in:

  • Antisense/siRNA/shRNA therapeutics
  • Reformulated cytotoxic agents
  • Radioconjugates